TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with ...

Shares of Biogen Inc. BIIB advanced 2.12% to $133.13 Friday, on what proved to be an all-around positive trading session for ...

Alex Fitzpatrick/Axios Massachusetts is home to 18 companies listed by Fortune as among the 500 largest in the nation. Why it matters: The Massachusetts economy is largely powered by medicine and ...

Cardiovascular disease and mental illness commonly co-occur. Addressing them together can improve both mental health and ...

The stock's fall snapped a three-day winning streak.

US stocks finished in the red on Thursday as investors turned cautious ahead of the non-farm payrolls report, while shares in ...

The global Oligonucleotide Synthesis Market, valued at US$8.9 billion in 2024 stood at US$10.5 billion in 2025 and is projected to advance at ...

The guideline recommendations advise universal use of hydroxychloroquine, minimizing steroids, and earlier introduction of ...

Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with Friedreich ataxia (FA) — a ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

The UK could lose out on £11 billion in pharmaceuticals research and development (R&D) investment by 2033, and see fewer new medicine launches in the NHS, unless very high and unpredictable medicines ...

DelveInsight's Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop ...